

#18C
DCC
10/27/02
ZRS
9/27/02



**Intellectual Property
Technology Law**

1414 Raleigh Road, Suite 201
Chapel Hill, NC 27517

P.O. Box 14329
Research Triangle Park, NC 27709

Phone: (919)419-9350
Fax: (919)419-9354
Info@iptl.com • www.iptl.com

Fax

To:	U.S. Patent and Trademark Office	From:	Marianne Fuierer
Fax:	703-746-3103	Date:	September 27, 2002
Phone:	Pages: (including this page) 37		
Re:	Response to November 8, 2001 Office Action	File:	4121-115

Original Document to: Follow via Regular Mail Follow via Express Mail Not to be sent (unless requested)

Comments:

Examiner Shukla:

Attached is the response that we faxed on March 8, 2002 along with confirmation receipt from the USPTO.

Thank you for calling and checking on the filing of this response.

Marianne Fuierer

A handwritten signature in black ink, appearing to read "Marianne Fuierer".

**CNFIDENTIALITY NOTE: THE INF RMATI N CONTAINED IN THIS FACSIMILE MESSAGE IS
CNFIDENTIAL INF RMATI N INTENDED NLY F R THE USE F THE INDIVIDUAL R ENTITY
NAMED AB VE. IF YOU HAVE RECEIVED THIS FACSIMILE IN ERROR PLEASE IMMEDIATELY NOTIFY
US BY TELEPHONE AND RETURN THE RGINAL MESSAGE TO US BY MAIL AT THE ADDRESS SET
UT AB VE.**

9/27/02
Sent by *[Signature]*

Commissioner for Patents
Washington, D.C. 20231

Sir:

This responds to the Office Action dated November 8, 2001 in the above-identified U.S. patent application.

An extension of time request under 37 CFR §1.136 is set forth in the penultimate paragraph of the REMARKS section hereof, extending the term for reply to the November 8, 2001 Office Action from February 8, 2002 to March 8, 2002.

In response to the Examiner's request for revision of the specification (see page 3, paragraph 5 of the November 8, 2001 Office Action), a substitute specification is enclosed in **APPENDIX A** hereof, complying with the requirements of 37 C.F.R. § 1.125(b), and a marked-up copy of the substitute specification is enclosed in **APPENDIX B** hereof, revised consistent with the Examiner's suggestions, and otherwise incorporating the amendments made herein. I hereby declare that this substitute specification submitted under the provisions of 37 CFR §1.125(b) contains no new matter (35 U.S.C. §132).

In response to the November 8, 2001 Office Action, please amend the application, as follows.

IN THE TITLE

Replace the Title: "Mammal with Inhibition of the Poly (ADP Ribose) Polymerase and Method For Using Same to Identify Cancerigenic Agents"

With --Mammal with Inhibition of the Poly (ADP Ribose) Polymerase and Method For Using Same to Identify Carcinogenic Agents--

IN THE ABSTRACT

Replace the originally filed Abstract of the Disclosure with the new Abstract of the Disclosure set forth in **APPENDIX C**. A marked-up version of the amended Abstract, showing the amendatory changes, is set forth in **APPENDIX D**.